Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Buy
61
BPMUF Quote, Financials, Valuation and Earnings
Last price:
$71.00
Seasonality move
:
2.93%
Day range:
$71.00 - $71.00
52-week range:
$47.50 - $74.00
Dividend yield:
0%
P/E ratio:
10.28x
P/S ratio:
3.61x
P/B ratio:
9.27x
Volume:
--
Avg. volume:
11
1-year change:
34.39%
Market cap:
$871.3M
Revenue:
$236.8M
EPS (TTM):
$6.89
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Basilea Pharmaceutica AG has -- downside to fair value with a price target of -- per share.
BPMUF vs. S&P 500
-
Over the past 5 trading days, Basilea Pharmaceutica AG has overperformed the S&P 500 by 1.46% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Basilea Pharmaceutica AG does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Basilea Pharmaceutica AG revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Basilea Pharmaceutica AG reported revenues of --.
Earnings Growth
-
Basilea Pharmaceutica AG has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Basilea Pharmaceutica AG reported earnings per share of --.
Enterprise value:
803.3M
EV / Invested capital:
--
Price / LTM sales:
3.61x
EV / EBIT:
10.97x
EV / Revenue:
3.42x
PEG ratio (5yr expected):
0.36x
EV / Free cash flow:
9.79x
Price / Operating cash flow:
10.94x
Enterprise value / EBITDA:
10.69x
Gross Profit (TTM):
$220.6M
Return On Assets:
-0.54%
Net Income Margin (TTM):
30.68%
Return On Equity:
-15.42%
Return On Invested Capital:
-0.84%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-06-30 | 2012-06-30 | 2013-06-30 | 2012-06-30 | 2013-06-30 | |
| Income Statement | ||||||
| Revenue | $101.5M | $70.2M | $50M | $32.4M | $21.8M | |
| Gross Profit | $99.2M | $63.2M | -- | $27M | $21.8M | |
| Operating Income | -$17.5M | -$80.1M | -$37.5M | -$35.5M | -$18.4M | |
| EBITDA | $112.1M | -$77.6M | -$36.3M | -$35.5M | -$18.4M | |
| Diluted EPS | $11.44 | -$8.39 | -$3.96 | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $239.1M | $221.9M | $206.6M | $172.4M | -- | |
| Total Assets | $246.7M | $247.4M | $255.8M | $209.9M | -- | |
| Current Liabilities | $40.9M | $162.9M | $74.7M | $42M | -- | |
| Total Liabilities | $332.2M | $317.7M | $239.1M | $191.2M | -- | |
| Total Equity | -$85.5M | -$70.4M | $16.7M | $18.7M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-06-30 | 2012-06-30 | 2013-06-30 | 2012-06-30 | 2013-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $48.4M | -$102.6M | $170.8M | -$49.4M | -$35.6M | |
| Cash From Investing | -$52.5M | $82M | -$43.3M | -$57.5M | -$218.8K | |
| Cash From Financing | $147.7K | -- | -$50.7M | -$110 | -$50.3M | |
| Free Cash Flow | $45.8M | -$105.4M | $169.7M | -$49.9M | -$35.9M | |
BPMUF
Sector
Market Cap
$871.3M
$23.4M
Price % of 52-Week High
95.95%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-0.11%
-1.64%
1-Year Price Total Return
34.39%
-21.81%
Beta (5-Year)
0.322
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$71.00
200-day SMA
Buy
Level
$62.10
Bollinger Bands (100)
Buy
Level
60.79 - 69.65
Chaikin Money Flow
Buy
Level
7.7K
20-day SMA
Buy
Level
$70.73
Relative Strength Index (RSI14)
Buy
Level
63.10
ADX Line
Buy
Level
32.84
Williams %R
Neutral
Level
-47.3186
50-day SMA
Buy
Level
$66.90
MACD (12, 26)
Buy
Level
1.11
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Sell
Level
-79K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.5951)
Sell
CA Score
(Annual)
Level (-0.3784)
Sell
Beneish M-Score
(Annual)
Level (5.8282)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-0.6271)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Basilea Pharmaceutica AG engages in the discovery, development, and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000 and is headquartered in Allschwil, Switzerland.
Stock Forecast FAQ
In the current month, BPMUF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BPMUF average analyst price target in the past 3 months is --.
-
Where Will Basilea Pharmaceutica AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Basilea Pharmaceutica AG share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Basilea Pharmaceutica AG?
Analysts are divided on their view about Basilea Pharmaceutica AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Basilea Pharmaceutica AG is a Sell and believe this share price will rise from its current level to --.
-
What Is Basilea Pharmaceutica AG's Price Target?
The price target for Basilea Pharmaceutica AG over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BPMUF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Basilea Pharmaceutica AG is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of BPMUF?
You can purchase shares of Basilea Pharmaceutica AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Basilea Pharmaceutica AG shares.
-
What Is The Basilea Pharmaceutica AG Share Price Today?
Basilea Pharmaceutica AG was last trading at $71.00 per share. This represents the most recent stock quote for Basilea Pharmaceutica AG. Yesterday, Basilea Pharmaceutica AG closed at $71.00 per share.
-
How To Buy Basilea Pharmaceutica AG Stock Online?
In order to purchase Basilea Pharmaceutica AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BPMUF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BPMUF
Sector
P/E ratio
10.28x
23.34x
PEG ratio
0.36x
-0.01x
P/B ratio
9.27x
1.72x
Price / LTM sales
3.61x
1.51x
Growth Metrics
BPMUF
Sector
Revenue growth
--
3.21%
Earnings growth
--
10.12%
Revenue (5-year growth)
11.86%
6.27%
Earnings forecast
--
-$0.19
Profitability
BPMUF
Sector
Profitability FY 2024
$192.9M
$2.7M
Return on invested capital
-0.84%
-33.62%
Return on assets
-0.54%
-29.68%
Return on equity
-15.42%
-38.89%
Earnings Date
Last Earnings Date
Aug
19
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Nov
18
Balance Sheet
BPMUF
Sector
Total cash
$70M
$25M
Short term investments
--
$23.9M
Total assets
$284.4M
$72.8M
Long term debt
--
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
66
DIOD alert for Feb 13
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
